Icu Medical, Inc. · NASDAQ:ICUI
Icu Medical — Raymond James 47th Annual Institutional Investors Conference 2026
15 slides from Icu Medical's conference presentation, Mar 2, 2026
Slide 1: Raymond James 2026 47th Annual Institutional Investors Conference
Raymond James 2026 47th Annual Institutional Investors Conference March 2nd, 2026 1
Slide 2: Disclosures
Disclosures > Any statement concerning Management’s expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the stat ement to be a re
Slide 3: ICU Medical at a Glance
ICU Medical at a Glance We are a global MedTech company focused on providing IV therapy and other critical care products across the continuum of care NASDAQ: ICUI | HQ: San Clemente, CA | ~14,000 Employees | >100 Countries with ICUI Sales Revenue by Segment Globally Diversified Recurring Revenue Con
Slide 4: IV Therapy: Structurally Attractive Industry, Clinically Essential Products
IV Therapy: Structurally Attractive Industry, Clinically Essential Products IV Solutions Sticky Demand Drivers IV Accessories > Essential products; >90% patients receive IV therapy > Strong incumbency advantage due to cost of change IV Pumps and Dedicated Sets > Long product and contract cycles IV-E
Slide 5: Built Through Focused Innovation and Acquisitions
Built Through Focused Innovation and Acquisitions From IV Component Supplier to Full Line Infusion Provider Innovation Across High-Impact Categories 2025 2012 ~$2.1B Revenue ~$200M Revenue Complete IV Therapy Portfolio IV Connector Manufacturing Specialty Consumables and Next-Generation IV Systems &
Slide 6: Well Positioned with a Right to Win
Well Positioned with a Right to Win Consumables Systems Vital Care Revenue > ~$1.1B > ~$685M (~60% Disposable Revenue) > ~$300M TTM Growth Rate > 6% > 5% > (4%) Key Products > Needlefree IV connectors and > Disposable dedicated sets > Anesthesia and respiratory disposables non-dedicated IV sets > La
Slide 7: Company Priorities
Company Priorities Commercial Deliver consistent core Momentum revenue growth Continued Realize both incremental and Innovation step change innovation Improved Expand gross margins and Financial Profile improve free cash flow 7
Slide 8: Commercial Momentum | Deliver Consistent Core Revenue Growth
Commercial Momentum | Deliver Consistent Core Revenue Growth Mid-single-digit growth across core business Consumables Systems > New Clave labeling claims from > Unique LVP market opportunity peer-reviewed clinical evidence > Systems wins pull through Competitive Share Gains > Deepen account penetrat
Slide 9: Continued Innovation | Realizing a New IV Therapy Platform
Continued Innovation | Realizing a New IV Therapy Platform 2023 Pump Portfolio Today: the IV Performance Platform > Full IV pump portfolio > Most precise pump for each infusion type > Unique workflows and UI > Ease of use with shared, intuitive UI > Managed by separate software > Single shared cloud
Slide 10: Continued Innovation | Attractive Product Cycle
Continued Innovation | Attractive Product Cycle Multi-year Accretive Refresh of Customer Base > Install base aged and poised for refresh > Attractive new technology with accretive ASP and margin profile Enables New Competitive Share Gains > Newest technology on long product cycles > Positive custome
Slide 11: Continued Innovation | Additional Software Opportunities
Continued Innovation | Additional Software Opportunities Enabling Deeper Clinical Integration into Connected Care Ecosystem Anesthesia & IV-EHR Interoperability Alert Other Therapy Forwarding Devices Biomedical Cybersecurity Reporting Real-Time Analytics and Location Services Clinical Dashboards Pat
Slide 12: Continued Innovation | Create Clinical Value with IV Consumables Innovation
Continued Innovation | Create Clinical Value with IV Consumables Innovation Addressing Impactful Clinical Priorities Example: Closing Safety Gaps in IV Workflows Patient and Clinician Safety > Reduce infection risk and catheter complications Integrating Core Safety Consumables > Protect medication i
Slide 13: Improved Financial Profile | Opportunities for Margin Expansion and Capital Allocation
Improved Financial Profile | Opportunities for Margin Expansion and Capital Allocation Expand Gross Margin Efficient Cash and Capital Structure Achieve Target Leverage +200bps Expansion Opportunity Remaining Levers for FCF Improvement Goal to Return Cash to Shareholders > Production & supply chain c
Slide 14: Why Invest in ICU Medical?
Why Invest in ICU Medical? Inflection point of new product cycle, improving financials, and increasing optionality New Product Cycles and Exiting Merger Integration Improving Cash Flow Optionality on Capital Steady Recurring Revenues Period (Last 3 Years) and EPS Allocation and Return > Plum Duo/Sol
Slide 15: Raymond James 2026 47th Annual Institutional Investors Conference
Raymond James 2026 47th Annual Institutional Investors Conference March 2nd, 2026 15
ICU Medical — Raymond James 47th Annual Institutional Investors Conference 2026 on 6ix